Literature DB >> 8905475

Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency.

A Sartorio1, S Ortolani, A Conti, R Cherubini, E Galbiati, G Faglia.   

Abstract

Lumbar spine, whole proximal femur and total body bone mineral density (BMD, g/cm2) and the regional soft tissue composition were measured with dual energy X-ray absorptiometry (Hologic QDR 1000/W) in eight adults with childhood onset GHD, before and after 6 months of recombinant GH treatment (0.5 IU/kg/week). Data obtained from patients were compared with those recorded in an age and sex matched control group. Before treatment, lumbar (L2-L4) spine BMD (mean +/- SD: 0.811 +/- 0.159 g/cm2), whole proximal femur BMD (0.739 +/- 0.094 g/cm2) and total body BMD (0.946 +/- 0.087 g/cm2) of patients were significantly (p < 0.001, 0.01 and 0.001, respectively) lower than those recorded in an age- and sex-matched control group (1.077 +/- 0.155 g/cm2, 0.968 +/- 0.166 g/cm2 and 1.168 +/- 0.058 g/cm2, respectively), although three patients showed BMD values at the lower limit of the normal range. Mean lumbar spine BMD, whole proximal femur BMD and total body BMD did not significantly change alter 6 months' GH treatment (-1.4 +/- 3.7%, +2.7 +/- 3.7% and -1.1 +/- 5.0% vs basal values, respectively). On the other hand, trochanteric subregion showed a significant 4.8 +/- 5.3% increase (vs basal, p < 0.05), while other hip subregions did not show significant changes. GH therapy caused marked effects on body composition; in fact, a significant decrease (p < 0.01) of trunk fat (-25.2 +/- 15.0%) and a marked increase (p < 0.01) of limbs lean mass (+10.0 +/- 5.3%), resulting in a significant (p < 0.02) reduction (-16.5 +/- 13.5%) of the axial to peripheral fat ratio (APFR), were clearly evident after six months of therapy. In conclusion, our study shows that six months of GH treatment do not exert relevant effects on the BMD of adults with childhood onset GHD. On the contrary, the effects of GH therapy on body composition are more marked, being clearly appreciable after six months of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905475     DOI: 10.1007/BF03349011

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.

Authors:  P Bergmann; J Valsamis; J Van Perborgh; J De Schepper; G Van Vliet
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

Review 2.  Growth hormone, insulin-like growth factor I, and bone: a clinical review.

Authors:  A G Johansson; E Lindh; S Ljunghall
Journal:  J Intern Med       Date:  1993-12       Impact factor: 8.989

3.  Bone mineral status in growth hormone deficiency.

Authors:  R M Shore; R W Chesney; R B Mazess; P G Rose; G J Bargman
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

Review 4.  Growth hormone (replacement) therapy in adults: bone and calcium metabolism.

Authors:  E A van der Veen; J C Netelenbos
Journal:  Horm Res       Date:  1990

5.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

6.  Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.

Authors:  D J O'Halloran; A Tsatsoulis; R W Whitehouse; S J Holmes; J E Adams; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  1993-05       Impact factor: 5.958

7.  Effects of short term administration of recombinant human growth hormone to elderly people.

Authors:  R Marcus; G Butterfield; L Holloway; L Gilliland; D J Baylink; R L Hintz; B M Sherman
Journal:  J Clin Endocrinol Metab       Date:  1990-02       Impact factor: 5.958

8.  Reduced bone mineral content in adult patients with growth hormone deficiency.

Authors:  T Rosén; T Hansson; H Granhed; J Szucs; B A Bengtsson
Journal:  Acta Endocrinol (Copenh)       Date:  1993-09

9.  Reduced bone mineral density in patients with adult onset growth hormone deficiency.

Authors:  S J Holmes; G Economou; R W Whitehouse; J E Adams; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

View more
  5 in total

1.  Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Authors:  A Sartorio; G Conte; A Conti; A Masala; S Alagna; P Rovasio; G Faglia
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

2.  Effects of growth hormone on bone modeling and remodeling in hypophysectomized young female rats: a bone histomorphometric study.

Authors:  Lysette Iglesias; James K Yeh; Mariano Castro-Magana; John F Aloia
Journal:  J Bone Miner Metab       Date:  2010-07-23       Impact factor: 2.626

3.  Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.

Authors:  S Longobardi; F Di Rella; R Pivonello; C Di Somma; M Klain; L Maurelli; R Scarpa; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

Review 4.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

5.  Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.

Authors:  A Sartorio; S Ortolani; E Galbiati; G Conte; V Vangeli; M Arosio; S Porretti; G Faglia
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.